DMAQR — Deep Medicine Acquisition Income Statement
0.000.00%
Last trade - 00:00- $57.84m
- $52.90m
- 41
- 54
- 59
- 50
Annual income statement for Deep Medicine Acquisition, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||
| Total Operating Expenses | 0.059 | 0.41 | 2.17 |
| Operating Profit | -0.059 | -0.41 | -2.17 |
| Total Net Non Operating Interest Income / Expense | |||
| Net Income Before Taxes | -0.059 | -0.414 | -0.343 |
| Provision for Income Taxes | |||
| Net Income After Taxes | -0.059 | -0.414 | -0.4 |
| Net Income Before Extraordinary Items | |||
| Net Income | -0.059 | -0.414 | -0.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -0.059 | -0.414 | -0.4 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -0.004 | -0.025 | -0.03 |
| Dividends per Share |